within Pharmacolibrary.Drugs.ATC.L;

model L01XX58
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 0.00023000000000000003,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.048,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.012166666666666666,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX58</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Epacadostat is an orally-administered, selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor developed for cancer immunotherapy. It was primarily investigated in combination with immune checkpoint inhibitors for the treatment of advanced malignancies such as melanoma. As of 2024, epacadostat is not approved for use due to failure to meet efficacy endpoints in major clinical trials.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients after oral administration; data compiled from phase 1 and phase 2 studies.</p><h4>References</h4><ol><li><p>Zhang, Y, et al., &amp; Tian, J (2021). Pharmacokinetics of S-epacadostat, an indoleamine 2,3-dioxygenase 1 inhibitor, in dog plasma and identification of its metabolites in vivo and in vitro. <i>Biomedical chromatography : BMC</i> 35(12) e5226–None. DOI:<a href=&quot;https://doi.org/10.1002/bmc.5226&quot;>10.1002/bmc.5226</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34388261/&quot;>https://pubmed.ncbi.nlm.nih.gov/34388261</a></p></li><li><p>Doi, T, et al., &amp; Yamamoto, N (2021). The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434). <i>Investigational new drugs</i> 39(1) 152–162. DOI:<a href=&quot;https://doi.org/10.1007/s10637-020-00942-1&quot;>10.1007/s10637-020-00942-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32564277/&quot;>https://pubmed.ncbi.nlm.nih.gov/32564277</a></p></li><li><p>Ye, K, et al., &amp; Zhang, K (2023). Design, synthesis, biological evaluation of urea substituted 1,2,5-oxadiazole-3-carboximidamides as novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors. <i>European journal of medicinal chemistry</i> 250 115217–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ejmech.2023.115217&quot;>10.1016/j.ejmech.2023.115217</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36842272/&quot;>https://pubmed.ncbi.nlm.nih.gov/36842272</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX58;
